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Abstract
Canada’s federal government intends to take steps to implement national pharmacare so that all Canadians 
have prescription drug coverage they need at an affordable price. Relatively limited funds have so far been 
pledged to support national pharmacare, which raises the question: what kind of program is envisioned? Since 
the government has already introduced regulations intended to reduce new drug prices drastically, national 
pharmacare seems likely to be a basic system designed to assist low-income Canadians with accessing primary 
care medicines. What Canadians actually need is a system that provides access to the medicine considered 
appropriate by the patient and their healthcare provider for the patient’s specific condition. Equitable national 
pharmacare will not be achieved if patients are denied access to new high-cost specialized medicines that can 
improve or extend their lives, any more than if patients who cannot afford basic drugs are not helped. 
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Two recent IJHPM articles focused on issues around the creation of national pharmacare in Canada. Lewis1 discussed issues in establishing a single-payer 
government drug insurance program, while Hajizadeh 
and Edmonds2 examined existing differences in out-of-
pocket expenditures on pharmaceuticals. Both articles raise 
important concerns. 
Government Insurance for Prescription Medicines
Canada has a universal government healthcare insurance 
scheme that covers physician, hospital (including medicines 
administered there) and laboratory services but not 
medicines dispensed in the community. Federal, provincial 
and territorial (FPT) governments have prescription drug 
plans that offer a degree of coverage to about a quarter of the 
population comprising seniors, social assistance recipients 
and some special groups such as cancer patients or when costs 
are deemed catastrophic. 
Several barriers must be overcome by pharmaceutical 
manufacturers to have a drug listed on government 
formularies, the first being health technology assessment 
(HTA). To be considered for coverage in all government 
plans, except those in Quebec, manufacturers submit an 
HTA application to the Canadian Agency for Drugs and 
Technologies in Health (CADTH) to demonstrate the 
medicine’s value based on its clinical benefit relative to its cost 
(Quebec has its own HTA agency). Lewis praised CADTH 
as having “excellent drug assessment expertise,”1 but ignores 
the fact that CADTH is owned and funded by FPT health 
ministries and, consequently, does not operate at arms-length 
from them. This results in its processes failing to adhere to 
good governance principles, particularly accountability, 
transparency, and stakeholder participation,3 which has led to 
criticism from patients and others, especially regarding how 
CADTH assesses high-cost rare disorder drugs.4,5 
Following HTA, manufacturers usually seek admission to 
the FPT governments’ collective price negotiating process, 
known as the pan-Canadian Pharmaceutical Alliance 
(pCPA), whose main objective is to capitalize on the 
combined governments’ buying power. Each provincial drug 
plan decides at the beginning of a negotiation whether to be 
included. If a negotiation is successfully completed, the cost 
and criteria under which FPT governments will pay for the 
drug are agreed. CADTH and the pCPA are closely connected 
so that, in general, a negative HTA recommendation results 
in no negotiation and a positive one sets up negotiating 
factors, usually the need for a substantial price reduction.6 A 
successful pCPA negotiation does not guarantee that all FPT 
plans will cover the medicine because an individual agreement 
must be reached with each plan because drug coverage is a 
provincial decision. Since the process is confidential, it is not 
known whether a drug is not listed by a drug plan because the 
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province opted out of the negotiation, or whether it opted in 
but failed to complete an agreement with the manufacturer.
Moreover, coverage does not mean that patients necessarily 
have easy and inexpensive access. FPT government plans have 
complex systems of deductibles, copayments and premiums 
and, for many medications, restricted access criteria that 
result in variation in patient eligibility, out-of-pocket expenses 
and coverage, which has led to inequalities in what drugs are 
covered, who gets access, and out-of-pocket costs between 
plans.7 Hajizadeh and Edmonds2 see national pharmacare as a 
way to reduce variation in out-of-pocket expenditures. 
Private Insurance for Prescription Medicines
Coverage of medicines is also available through private 
insurance paid for by individuals themselves or cost-shared 
with their employers, unions or associations. Over two-thirds 
of Canadians have access to private insurance through a range 
of plans from those that offer relatively limited drug coverage 
to those that cover virtually all medicines with regulatory 
approval, the extent of each plan’s coverage being determined 
by how much clients are willing to pay in premiums. Some 
private plans have lifetime caps of a set amount, meaning 
that the company will only cover a high-cost drug for a few 
years after which the patient is faced with paying or not 
having the medicine.8 Insurance companies take note of HTA 
recommendations but do not necessarily base coverage on 
them. 
Private insurers are thought to pay higher prices than 
government plans, which is one reason why Lewis believes 
private insurance plans are inefficient and should be replaced 
by a national government plan.1 Another reason is that only a 
small proportion of all new drugs offer substantial therapeutic 
benefits over existing medicines, although innovative drugs 
for rare diseases for which there are no existing therapies are 
likely to provide much greater benefit. Nevertheless, many 
Canadians rely on private insurance to access medicines 
they would otherwise be unable to due to cost or delays in 
government systems. For example, in an open letter to the 
Prime Minister, a cystic fibrosis sufferer, wrote: “I had a health 
crisis and was on the verge of expiring and requiring a lung 
transplant in 2012. I received access to the drug Kalydeco and 
my lung function bumped from 30% to 50% and has stayed 
at 50% since 2012. If I did not have an employer benefit plan 
and was forced to wait until Kalydeco was approved in 2014, I 
would have likely died well before the drug was approved for 
public reimbursement.”9 
A federal government seeking to replace private insurance 
with single-payer government-funded national pharmacare 
providing significantly less comprehensive coverage would be 
extremely unpopular.
Equality or Equity?
In the belief that national pharmacare would reduce 
inequalities in existing government programs, Lewis1 
and Hajizadeh and Edmonds,2 like many other Canadian 
academics, politicians, government officials and patients, 
want pharmacare incorporated within the existing healthcare 
system, although Lewis recognizes that stakeholder interests 
in keeping the status quo will present challenging difficulties. 
Equality means treating everyone exactly the same way. The 
risk of a system focused solely on equality is that it could just as 
well equally deny access to medicines to all patients as equally 
provide access. Significant improvements in equality could be 
realized within the present government drug plans without 
the need to replace them with an expensive new initiative. 
For instance, governments could eliminate deductibles and 
copayments for low-income Canadians or make clinical 
criteria required to obtain coverage for many drugs consistent 
in all plans. 
National pharmacare should be focused on equity, ie, 
it should be a fair and just system delivering medicines for 
everyone to benefit based on their need.10 Although it may be 
a difficult and complex task to achieve, the objective should 
be equity-based national pharmacare that would provide 
the medicine deemed appropriate by the patient and their 
healthcare provider for the patient’s specific condition. This 
type of program would not only provide coverage to patients 
who presently have none but would also extend appropriate 
coverage to patients whose insurance, whether government or 
private, denies access due to a drug’s high cost or limits access 
by requiring the patient’s circumstances to match clinical 
criteria that are overly restrictive or that make little clinical 
sense. This type of program would satisfy present unmet 
needs and be more likely to lead to appropriate prescribing 
and improved health outcomes, which should be a primary 
goal of all governments. As Lewis noted, Canada “can afford a 
generous program,”1 but will the federal government opt for a 
generous one or miserly one?
Affordability or Accessibility?
Canada’s federal government promotes “affordability, 
accessibility and appropriate use of prescription drugs,”11 
but affordability seems to be the main objective since drug 
costs in Canada are second only to the United States. The 
government sees the road to achieving accessibility as one 
in which affordability is attained by introducing new far-
reaching powers for the tribunal that sets price controls on 
new medicines. It intends to reduce the prices of new high 
priority medicines by “40% on average”12 which, in practice, 
means medicine developers may be required to drop prices by 
up to 70%, perhaps more.13 A reasonable reduction should be 
manageable, but 40%-70% is an unsustainable business model 
that will lead to manufacturers long delaying the launch of 
innovative medicines in Canada or not bringing them at all. 
Appropriate drug use is unattainable if Canadians cannot 
access new medicines because manufacturers avoid Canada 
due to punitive price controls. 
Many politicians, government officials and academics in 
Canada believe that, because pharmaceutical manufacturers 
seek regulatory approval in Europe before Canada and launch 
their products at lower prices than in Canada, introducing 
dramatically reduced drug prices in Canada will have little 
impact on how companies view the attractiveness of Canada 
as a market for their medicines. They ignore the facts that 
many western European countries present larger markets 
than Canada and have either pharmaceutical company 
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headquarters or major research and manufacturing facilities 
within their borders. All brand name companies in Canada 
are affiliates of manufacturers whose headquarters and main 
facilities are based in other countries. 
Canada is not in a strong position to demand major 
reductions in drug prices. A large survey of multi-national 
pharmaceutical executives in 31 markets performed in 2017 
drew attention to the fact that stiff price cuts levied against 
innovative drugs hamper a country’s ability to secure and 
sustain investment, and in particular noted that this should 
be a “red flag” to economies considering a similar approach 
“such as Canada in its proposed amendments” to the pricing 
tribunal.14 More recently, a preliminary report of a survey of 
global and Canadian pharmaceutical executives performed 
for Life Sciences Ontario about the new pricing regulations 
reported that 91% of the respondents foresee “no launch” 
decisions being made for Canada and 96% foresee delayed 
launches in Canada.15 
The 2017 survey of multi-national pharmaceutical executives 
reported that the pricing and reimbursement environment 
in New Zealand is highly damaging to innovators and the 
central factor undermining investment, with the use of direct 
price cuts and a narrow understanding of cost and savings 
particularly dissuading investment.14 Despite Canada having 
a larger population than New Zealand, enforcing drastically 
reduced drug prices in Canada will move the attractiveness of 
the country as a pharmaceutical market closer to the situation 
in New Zealand, a country whose price controls Lewis 
admires.1 New Zealand’s insurance program covers only a few 
drugs in each class and provides little access to new high-cost 
innovative medicines, including anti-cancer medications and 
drugs for rare disorders. When new drugs are listed, there 
is frequently a long delay.16 Pharmaceutical manufacturers 
seek regulatory approval for new drugs later in New Zealand 
than in Canada and, if they are not approved for insurance 
coverage, which many are not, they make them unavailable, 
thus reducing New Zealanders’ accessibility.17 While some 
indicators of public health are similar between Canada and 
New Zealand, New Zealanders with cardiovascular disorders, 
cancer and several other disease conditions have worse health 
outcomes in terms of disease survival than Canadians,18,19 
although it is difficult to assess with confidence that reduced 
drug access plays a role in these differences. 
In their recent election platform, the Liberals, who now 
form Canada’s federal government, promised a down payment 
of $6 billion to be shared among national pharmacare and 
other public health initiatives. Although $6 billion is a lot of 
money, it is just a drop in the bucket when compared with the 
$40 billion cost for pharmacare estimated by the government’s 
own Advisory Council on the Implementation of National 
Pharmacare (although some savings were anticipated),20 or 
the $48 to $52 billion projected by a tax consulting company 
for the Canadian Taxpayers Federation.21 
Despite mentioning high-cost specialized care drugs, the 
Advisory Council recommended pharmacare be launched by 
covering a short list of priority essential medicines and cited 
two potential starting points for creating the list: the World 
Health Organization’s Model List of Essential Medicines, 
which includes about 450 drugs intended as a formulary for 
developing countries, and a list of 125 primary care drugs 
developed by a group of Toronto clinicians. Neither list 
includes high-cost specialized care drugs. 
Medicines for common illnesses are essential and low-
income Canadians should not have to choose between paying 
for them or other life necessities. Nevertheless, innovative 
drugs for formerly untreatable disorders that save lives or 
significantly improve life quality are also vital. These new 
drugs can cost many thousands of dollars per year and 
frequently require life-long use, but without private or 
government insurance, they are unaffordable irrespective of 
whether a Canadian’s income is low, medium or high. It is 
these drugs with which provincial government premiers, who 
are unenthusiastic about a national program, want help from 
the federal government.22 
Conclusion
The primary aim of national pharmacare must not be 
confined to cost-containment but should be to ensure the 
best medicines are made accessible without excessively 
restrictive or nonsensical clinical criteria so that patients 
receive the most appropriate medicine depending on their 
individual situation. Equity-based national pharmacare will 
not be achieved if patients are denied access to new high-cost 
specialized medicines that can improve or extend their lives, 
any more than if patients who cannot afford basic primary 
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